Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol

References

• Wang W, Hu SS, Kong LZ et al. Summary of report on cardiovascular diseases in China, 2012. Biomed. Environ. Sci. 27(7), 552–558 (2014).
   PubMed Web of Science ®Google Scholar
• Szczepanski A, Huang J, Baer T et al. Retraction and republication – ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 385(9966), 402 (2015).
   PubMedGoogle Scholar
• Li D, Dong W, Chen Y et al. Effect of pathway training on rest heart rate and the application of beta-blocker in coronary heart disease patients: an open-label, multicenter, prospective study. Zhonghua yi xue za zhi 95(28), 2272–2276 (2015).
   PubMedGoogle Scholar
• Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype – a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307(25), 1558–1560 (1982).
   PubMed Web of Science ®Google Scholar
• Ray D, Wu A, Wilkinson JE et al. Aging in heterozygous Dnmt1-deficient mice: effects on survival, the DNA methylation genes and the development of amyloidosis. J. Gerontol. A Biol. Sci. Med. Sci. 61(2), 115–124 (2006).
   PubMed Web of Science ®Google Scholar
• Liu J, Liu ZQ, Tan ZR et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin. Pharmacol. Ther. 74(4), 372–379 (2003).
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: Clin. relevance. Curr. Oncol. Rep. 12(1), 7–15 (2010).
   PubMed Web of Science ®Google Scholar
• Llerena A, Dorado P, Penas-Lledo EM. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10(1), 17–28 (2009).
   PubMed Web of Science ®Google Scholar
• Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between east Asians and Caucasians and the role of genetic polymorphisms. J. Clin. Pharmacol. 44(10), 1083–1105 (2004).
   PubMed Web of Science ®Google Scholar
• Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46(3), 452–459 (1994).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496–526 (2007).
   PubMed Web of Science ®Google Scholar
• Bijl MJ, Visser LE, Van Schaik RH et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin. Pharmacol. Ther. 85(1), 45–50 (2009).
   PubMed Web of Science ®Google Scholar
• Wuttke H, Rau T, Heide R et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther. 72(4), 429–437 (2002).
   PubMed Web of Science ®Google Scholar
• Institute of Clinical Pharmacology, Central South University. www.csupharmacol.com.
   Google Scholar
• Jin SK, Chung HJ, Chung MW et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J. Clin. Pharm. Ther. 33(5), 567–573 (2008).
   PubMed Web of Science ®Google Scholar
• Bae SH, Lee JK, Cho DY, Bae SK. Simultaneous determination of metoprolol and its metabolites, alpha-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. J. Clin. Pharm. Ther. 37(11), 1256–1264 (2014).
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Hypertension: Management in Adults in Primary Care: Pharmacological Update. Royal College of Physicians of London., London, UK (2006).
   Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertension 27(11), 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Dalal JJ, Huang J et al. The role of beta-blockers in the management of hypertension: an Asian perspective. Curr. Med. Res. Opin. 27(5), 1021–1033 (2011).
   PubMed Web of Science ®Google Scholar
• Khan H, Kunutsor S, Kalogeropoulos AP et al. Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis. J. Am. Heart Assoc. 4(1), e001364 (2015).
   PubMed Web of Science ®Google Scholar
• Nanchen D, Stott DJ, Gussekloo J et al. Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. Eur. J. Heart Fail. 15(5), 581–588 (2013).
   PubMed Web of Science ®Google Scholar
• Dangdang L, Wei D, Yundai C et al. Effect of pathway training on rest heart rate and the application of β-blocker in coronary heart disease patients: an open-label, multicenter, prospective study. Natl Med. J. China 95(28), 2272–2276 (2015).
   Google Scholar
• Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J. 30(19), 2337–2345 (2009).
   PubMed Web of Science ®Google Scholar
• Steg PG, Ferrari R, Ford I et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PloS ONE 7(5), e36284 (2012).
   PubMed Web of Science ®Google Scholar
• Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. European J. Clin. Pharmacol. 63(4), 321–333 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P450 2D6 in ethnic populations. Drug Metab. Disposit. Biol. Fate Chem. 24(3), 350–355 (1996).
   PubMed Web of Science ®Google Scholar
• Ozdemir M, Crewe KH, Tucker GT, Rostami-Hodjegan A. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J. Clin. Pharmacol. 44(12), 1398–1404 (2004).
   PubMed Web of Science ®Google Scholar
• Wang H, Liu J, Liu K et al. Beta1-adrenoceptor gene Arg389Gly polymorphism and essential hypertension risk in general population: a meta-analysis. Mol. Biol. Rep. 40(6), 4055–4063 (2013).
   PubMed Web of Science ®Google Scholar
• Liu H, Xing X, Huang L, Huang Z, Yuan H. The expression level of myocardial beta1-adrenergic receptor affects metoprolol antihypertensive effects: a novel mechanism for interindividual difference. Med. Hypoth. 81(1), 71–72 (2013).
   PubMed Web of Science ®Google Scholar
• Lanfear DE, Peterson EL, Zeld N, Wells K, Sabbah HN, Williams K. Beta blocker survival benefit in heart failure is associated with ADRB1 Ser49Gly genotype. J. Cardiac Fail. 21(8), S50–S50 (2015).
   Web of Science ®Google Scholar
• Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinetics 48(11), 689–723 (2009).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25(4), 193–200 (2004).
   PubMed Web of Science ®Google Scholar
• Ji L, Pan S, Wu J, Marti-Jaun J, Hersberger M. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chinese Med. J. 115(12), 1780–1784 (2002).
   PubMed Web of Science ®Google Scholar
• Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatr. 25(5), 534–553 (2013).
   PubMed Web of Science ®Google Scholar
• Griese EU, Zanger UM, Brudermanns U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8(1), 15–26 (1998).
   PubMedGoogle Scholar
• Blake CM, Kharasch ED, Schwab M, Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin. Pharmacol. Ther. 94(3), 394–399 (2013).
   PubMed Web of Science ®Google Scholar
• Batty JA, Hall AS, White HL et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. Clin. Pharmacol. Ther. 95(3), 321–330 (2014).
   PubMed Web of Science ®Google Scholar
• Fux R, Morike K, Prohmer AM et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin. Pharmacol. Ther. 78(4), 378–387 (2005).
   PubMed Web of Science ®Google Scholar
• Zineh I, Beitelshees AL, Gaedigk A et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76(6), 536–544 (2004).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Pan HC, Chen YP et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 366(9497), 1622–1632 (2005).
   PubMed Web of Science ®Google Scholar
• Dai DP, Geng PW, Wang SH et al. In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population. Basic Clin. Pharmacol. Toxicol. 117(1), 39–43 (2015).
   PubMed Web of Science ®Google Scholar